| scholarly article | Q13442814 |
| P50 | author | Carol Aghajanian | Q91946596 |
| P2093 | author name string | Howard A Burris | |
| Jeffrey R Infante | |||
| Shannon R Morris | |||
| David S Hong | |||
| Lillian L Siu | |||
| Jennifer J Wheler | |||
| Joanna B Opalinska | |||
| Shubham Pant | |||
| Carla Kurkjian | |||
| Katherine M Bell-McGuinn | |||
| Ademi Santiago-Walker | |||
| Joyce M Antal | |||
| Jennifer L Gauvin | |||
| Lee-Ann Stayner | |||
| P2860 | cites work | First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors | Q27851678 |
| Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor | Q28540161 | ||
| The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma | Q34500544 | ||
| Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers | Q34518245 | ||
| A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities | Q35701021 | ||
| PI3K/Akt/mTOR pathway as a target for cancer therapy | Q36227186 | ||
| Perturbations of the AKT signaling pathway in human cancer | Q36313181 | ||
| Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors | Q38406496 | ||
| AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. | Q40824440 | ||
| Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors | Q42708700 | ||
| Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members | Q45267497 | ||
| Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. | Q48331212 | ||
| Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. | Q51329014 | ||
| A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors | Q84366967 | ||
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P577 | publication date | 2018-04-03 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. |
| Q90171463 | Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q90594555 | Targeting AKT for cancer therapy |
| Q58555910 | The Akt pathway in oncology therapy and beyond (Review) |
Search more.